Call Start: 08:00 January 1, 0000 9:07 AM ET Biogen Inc. (NASDAQ:BIIB) Q3 2021 Earnings Conference Call October 20, 2021, 08:00 AM ET Company Participants Michel Vounatsos – Chief Executive Officer Mike Hencke – Investor Relations Al Sandrock – Head of Research & Development Mike McDonnell – Chief Financial Officer Conference Call Participants Robyn Karnauskas – Analyst Michael Yee – Jefferies Cory Kasimov – JPMorgan Marc Goodman – SVB Leerink Matthew Harrison – Morgan Stanley Geoff Meacham – Bank of Americ ...

Biogen Inc. (NASDAQ:BIIB) Morgan Stanley 19th Annual Global Healthcare Conference September 9, 2021 9:30 AM ET Company Participants Michel Vounatsos - Chief Executive Officer Alisha Alaimo - President, Biogen U.S. Organization Conference Call Participants Matthew Harrison - Morgan Stanley Matthew Harrison Great. Good morning, everybody. Thanks for joining us for the next session this morning. I'm Matthew Harrison, one of the biotechs analysts here at Morgan Stanley. Very pleased to have Biogen with us th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 0-19311 BIOGEN INC. (Exact name of registrant as specified in its charter) Delaware 33-0112644 (State or other jurisdiction of incorporation or organization) (I.R.S. Employe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 0-19311 BIOGEN INC. (Exact name of registrant as specified in its charter) Delaware 33-0112644 (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Iden ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 0-19311 BIOGEN INC. (Exact name of registrant as specified in its charter) Delaware 33-0112644 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Id ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-19311 BIOGEN INC. (Exact name of registrant as specified in its charter) Delaware 33-0112644 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identi ...